CO4900046A1 - Antagonistas receptores de vitronectina - Google Patents

Antagonistas receptores de vitronectina

Info

Publication number
CO4900046A1
CO4900046A1 CO97057225A CO97057225A CO4900046A1 CO 4900046 A1 CO4900046 A1 CO 4900046A1 CO 97057225 A CO97057225 A CO 97057225A CO 97057225 A CO97057225 A CO 97057225A CO 4900046 A1 CO4900046 A1 CO 4900046A1
Authority
CO
Colombia
Prior art keywords
receptor antagonists
vitronectin receptor
chrg
alkenyl
alkyl
Prior art date
Application number
CO97057225A
Other languages
English (en)
Spanish (es)
Inventor
James Francis Callahan
Russell Donovan Cousins
Richard Mccullock Keenan
Kwon Chet
William Henry Miller
Irene N Uzinkas
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Publication of CO4900046A1 publication Critical patent/CO4900046A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/24Heavy metals; Compounds thereof
    • A61K33/243Platinum; Compounds thereof
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D223/00Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D223/00Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/14Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D223/16Benzazepines; Hydrogenated benzazepines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/582Recycling of unreacted starting or intermediate materials

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Inorganic Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CO97057225A 1996-10-02 1997-10-01 Antagonistas receptores de vitronectina CO4900046A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2732096P 1996-10-02 1996-10-02
US4377697P 1997-04-11 1997-04-11

Publications (1)

Publication Number Publication Date
CO4900046A1 true CO4900046A1 (es) 2000-03-27

Family

ID=26702318

Family Applications (1)

Application Number Title Priority Date Filing Date
CO97057225A CO4900046A1 (es) 1996-10-02 1997-10-01 Antagonistas receptores de vitronectina

Country Status (36)

Country Link
EP (1) EP0957917B1 (https=)
JP (2) JP4491072B2 (https=)
KR (1) KR100589578B1 (https=)
CN (1) CN1114403C (https=)
AP (1) AP1463A (https=)
AR (1) AR008878A1 (https=)
AT (1) ATE312089T1 (https=)
AU (1) AU733417B2 (https=)
BG (1) BG64581B1 (https=)
BR (1) BR9712248B1 (https=)
CA (1) CA2267224C (https=)
CO (1) CO4900046A1 (https=)
CY (1) CY2576B1 (https=)
CZ (1) CZ299076B6 (https=)
DE (1) DE69734833T2 (https=)
DK (1) DK0957917T3 (https=)
DZ (1) DZ2320A1 (https=)
EA (1) EA002419B1 (https=)
ES (1) ES2252775T3 (https=)
HU (1) HU229221B1 (https=)
ID (1) ID19623A (https=)
IL (1) IL129243A (https=)
MA (1) MA24361A1 (https=)
MY (1) MY137606A (https=)
NO (1) NO320194B1 (https=)
NZ (1) NZ334953A (https=)
PE (1) PE10499A1 (https=)
PL (1) PL190859B1 (https=)
RO (1) RO119881B1 (https=)
SA (1) SA98180936B1 (https=)
SK (1) SK285029B6 (https=)
TR (1) TR199900737T2 (https=)
TW (1) TW487702B (https=)
UA (1) UA60311C2 (https=)
UY (2) UY24735A1 (https=)
WO (1) WO1998014192A1 (https=)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA60311C2 (uk) * 1996-10-02 2003-10-15 Смітклайн Бічам Корпорейшн Антагоністи рецептора вітронектину, спосіб одержання цих сполук та фармацевтична композиція
TW527355B (en) 1997-07-02 2003-04-11 Bristol Myers Squibb Co Inhibitors of farnesyl protein transferase
CN1273529A (zh) * 1997-09-24 2000-11-15 史密丝克莱恩比彻姆公司 玻连蛋白受体拮抗剂
AU9578798A (en) * 1997-09-24 1999-04-12 Smithkline Beecham Corporation Vitronectin receptor antagonist
US6372719B1 (en) 1998-03-04 2002-04-16 Jay Cunningham ανβ3 integrin antagonists in combination with chemotherapeutic agents
DE19842415A1 (de) * 1998-09-16 2000-03-23 Merck Patent Gmbh Pharmazeutische Zubereitung
AU2592600A (en) * 1998-12-23 2000-07-31 G.D. Searle & Co. Method of using an integrin antagonist and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
AU747503B2 (en) * 1999-02-03 2002-05-16 Merck & Co., Inc. Benzazepine derivatives as alpha-V integrin receptor antagonists
JP5127096B2 (ja) * 1999-04-30 2013-01-23 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン アポトーシスにより誘導される自己免疫疾患を処置するためのベンゾジアゼピンの使用
AU6523200A (en) * 1999-08-06 2001-03-05 Smithkline Beecham Corporation Vitronectin receptor antagonists useful for the treatment of strokes
US6514964B1 (en) 1999-09-27 2003-02-04 Amgen Inc. Fused cycloheptane and fused azacycloheptane compounds and their methods of use
DE10028575A1 (de) 2000-06-14 2002-03-14 Basf Ag Integrinliganden
DE10027514A1 (de) * 2000-06-06 2002-01-03 Basf Ag Liganden von Integrinrezeptoren
FR2806082B1 (fr) * 2000-03-07 2002-05-17 Adir Nouveaux composes bicycliques antagonistes des recepteurs de la vitronectine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
CA2436130A1 (en) 2001-01-29 2002-08-08 Ortho-Mcneil Pharmaceutical, Inc. Substituted indoles and their use as integrin antagonists
KR20030087069A (ko) * 2001-04-10 2003-11-12 스미스클라인 비참 코포레이션 유착 형성을 억제하는 방법
SE0101386D0 (sv) 2001-04-20 2001-04-20 Astrazeneca Ab New compounds
WO2002090325A2 (en) * 2001-05-03 2002-11-14 Merck & Co., Inc. Benzazepinone alpha v integrin receptor antagonists
EP1443963B1 (en) 2001-10-22 2014-05-21 The Scripps Research Institute Antibody targeting compounds
GB0215867D0 (en) * 2002-07-09 2002-08-14 Glaxosmithkline Spa Novel method and compounds
WO2004089890A2 (en) * 2003-04-04 2004-10-21 Smithkline Beecham Corporation Process and intermediates for preparing benzazepines
AU2005229015C1 (en) * 2004-04-02 2013-01-17 The Regents Of The University Of California Methods and compositions for treating and preventing disease associated with alphaVbeta5 integrin
AU2012216372B2 (en) * 2004-04-02 2015-01-22 The Regents Of The University Of California Methods and compositions for treating and preventing disease associated with alphaVbeta5 integrin
UA87854C2 (en) 2004-06-07 2009-08-25 Мерк Энд Ко., Инк. N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators
AR052823A1 (es) * 2004-12-21 2007-04-04 Smithkline Beecham Corp Uso de un antagonista del receptor de vitronectina para l a preparacion de una formulacion farmaceutica util para inhibir el exceso de formacion de cicatrices en la piel de a un mamifero y dicha formulacion
EA016227B1 (ru) * 2005-11-29 2012-03-30 Смитклайн Бичем Корпорейшн Способ лечения офтальмологических неоваскулярных расстройств
EP2730282A1 (en) 2007-11-08 2014-05-14 The General Hospital Corporation Methods and compositions for the treatment of proteinuric diseases
AU2008321770B2 (en) * 2007-11-16 2012-09-06 Ube Industries, Ltd. Benzazepinone compound
US8076475B2 (en) * 2008-03-06 2011-12-13 Glaxosmithkline Llc Process
JP2012517447A (ja) 2009-02-10 2012-08-02 ザ スクリプス リサーチ インスティチュート 化学的にプログラムされたワクチン接種法
AU2010231631A1 (en) * 2009-03-30 2011-11-10 Ube Industries, Ltd. Pharmaceutical composition for treatment or prevention of ophthalmic diseases
JP5572996B2 (ja) * 2009-05-15 2014-08-20 宇部興産株式会社 ベンズアゼピノン化合物を有効成分として含有する医薬
EP2456460A4 (en) 2009-07-24 2013-02-20 Univ California METHOD AND COMPOSITIONS FOR TREATING AND PREVENTING DISEASES ASSOCIATED WITH AVB5 INTEGRIN
WO2011062765A2 (en) 2009-11-17 2011-05-26 The Regents Of The University Of Michigan 1,4-benzodiazepine-2,5-diones and related compounds with therapeutic properties
EP2325194A1 (en) * 2009-11-24 2011-05-25 Glycotope GmbH Process for the purification of glycoproteins
ES2864079T3 (es) 2014-05-30 2021-10-13 Pfizer Derivados de carbonitrilo como moduladores selectivos del receptor de andrógenos
JP7693709B2 (ja) * 2020-04-26 2025-06-17 ジャンスー・エンファ・ファーマシューティカル・カンパニー・リミテッド 1,5-ジヒドロ-2,4-ベンゾジアゼピン-3-オン誘導体及びその使用
WO2023275715A1 (en) 2021-06-30 2023-01-05 Pfizer Inc. Metabolites of selective androgen receptor modulators

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2197160T3 (es) * 1992-12-21 2004-01-01 Smithkline Beecham Corp Antagonistas fibronogeno bicicliclos.
NZ290008A (en) * 1994-06-29 1998-08-26 Smithkline Beecham Corp Vitronectin receptor antagonists, comprising a fibrinogen antagonist analogue linked to a heterocycle
ZA955391B (en) * 1994-06-29 1996-02-09 Smithkline Beecham Corp Vitronectin receptor antagonists
JPH10504825A (ja) * 1994-08-22 1998-05-12 スミスクライン・ビーチャム・コーポレイション 二環式化合物
WO1996026190A1 (en) * 1995-02-22 1996-08-29 Smithkline Beecham Corporation Integrin receptor antagonists
UA60311C2 (uk) * 1996-10-02 2003-10-15 Смітклайн Бічам Корпорейшн Антагоністи рецептора вітронектину, спосіб одержання цих сполук та фармацевтична композиція

Also Published As

Publication number Publication date
NO320194B1 (no) 2005-11-14
CN1238689A (zh) 1999-12-15
JP4491072B2 (ja) 2010-06-30
UA60311C2 (uk) 2003-10-15
IL129243A0 (en) 2000-02-17
SK285029B6 (sk) 2006-04-06
PL190859B1 (pl) 2006-02-28
SK42599A3 (en) 1999-12-10
TW487702B (en) 2002-05-21
HK1023730A1 (en) 2000-09-22
CZ113299A3 (cs) 2000-03-15
BR9712248A (pt) 1999-08-24
AU4746297A (en) 1998-04-24
NZ334953A (en) 2000-01-28
UY24935A1 (es) 2001-07-31
DK0957917T3 (da) 2006-04-18
DE69734833D1 (de) 2006-01-12
HU229221B1 (en) 2013-09-30
EP0957917A1 (en) 1999-11-24
EP0957917B1 (en) 2005-12-07
BR9712248B1 (pt) 2010-06-29
ID19623A (id) 1998-07-23
IL129243A (en) 2004-07-25
CA2267224A1 (en) 1998-04-09
BG64581B1 (bg) 2005-08-31
RO119881B1 (ro) 2005-05-30
EA199900356A1 (ru) 2000-02-28
BG103299A (en) 2000-01-31
CA2267224C (en) 2007-03-13
JP2010006838A (ja) 2010-01-14
SA98180936B1 (ar) 2006-05-30
ATE312089T1 (de) 2005-12-15
ES2252775T3 (es) 2006-05-16
MY137606A (en) 2009-02-27
AU733417B2 (en) 2001-05-17
AP9901493A0 (en) 1999-03-31
HUP9903769A2 (hu) 2000-03-28
NO991590D0 (no) 1999-03-31
AP1463A (en) 2005-09-10
EP0957917A4 (en) 2002-05-15
JP2001501936A (ja) 2001-02-13
HUP9903769A3 (en) 2000-07-28
TR199900737T2 (xx) 1999-07-21
KR100589578B1 (ko) 2006-06-15
EA002419B1 (ru) 2002-04-25
NO991590L (no) 1999-05-31
AR008878A1 (es) 2000-02-23
DZ2320A1 (fr) 2002-12-28
CY2576B1 (en) 2008-07-02
CN1114403C (zh) 2003-07-16
PE10499A1 (es) 1999-03-27
KR20000048816A (ko) 2000-07-25
MA24361A1 (fr) 1998-07-01
DE69734833T2 (de) 2006-07-13
WO1998014192A1 (en) 1998-04-09
CZ299076B6 (cs) 2008-04-16
PL332674A1 (en) 1999-09-27
UY24735A1 (es) 1998-03-30

Similar Documents

Publication Publication Date Title
CO4900046A1 (es) Antagonistas receptores de vitronectina
CO5180550A1 (es) Inhibidores de fab i
PE46899A1 (es) Derivados de n-fenil-sulfonamida
FI943247A0 (fi) Piperatsiinijohdannaisia 5-HT-reseptoriantagonisteina
AR240929A2 (es) "n-piridinsulfonil-n'-piridinil-y-triazinil-ureas procedimiento parasu preparacion, intermediarios para uso exclusivo en dicho procedimiento, y composiciones que contienen dichas ureas"
AR013493A1 (es) COMPUESTO DE QUINOLONA, SU USO PARA LA FABRICACIoN DE UN MEDICAMENTO Y COMPOSICIoN FARMACEUTICA QUE LO COMPRENDE
AR011229A1 (es) Compuestos derivados de adenosina antagonistas en el receptor ai adenosina, procesos para su preparacion, composiciones farmaceuticas que los contieneny su uso en medicina.
NZ511394A (en) N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
AR026352A1 (es) Derivados de imidazopiridina como inhibidores de la fosfodiesterasa vii.
AR017798A1 (es) Agonistas de receptores adrenergicos beta 3, selectivos, utiles para el tratamiento de la diabetes ii y la obesidad
ATE144776T1 (de) Verwendung von phospholipid-derivaten als antivirale arzneimittel und neue phospholipide
ES2014482B3 (es) Nuevas 2-tiazolil imidazo/1,2-a/pirimidinas y sus sales, su procedimiento de preparacion, su aplicacion a titulo de medicamentos y las composiciones que las encierran.
ES524386A0 (es) Procedimiento para la obtencion de muramilpeptidos
ES2167617T3 (es) Derivados de 1-bencenosulfonilpirrolidina como antagonistas del receptor de la bradiquinina.
ES556351A0 (es) Un procedimiento para preparar derivados de pirrolidona
AR028968A1 (es) Derivados heterociclicos de la aminoalquilpiridina como psicofarmacos
CO4970706A1 (es) Procedimiento de preparacion de compuestos de [2,3-d] pirimidinas 5-sustituidos por derivados de acido hidroxamico e intermediarios de reaccion
PT1338596E (pt) Processos para a preparacao de agentes antibacterianos do tipo carbapenem
CO5180536A1 (es) Inhibidores de proteasas catepsina
MX9307309A (es) Derivados de pirrolo, su preparacion y su aplicacion en terapeutica.
ES515640A0 (es) "un procedimiento para la preparacion de pirimid-2-onas".
ES2039618T3 (es) Un procedimiento para la preparacion de agentes antiarritmicos.
AR016013A1 (es) Pirazolil-pirazoles sustituidos con 1-metil-5-alquilsulfonilo, 1-metil-5-alquilsulfinilo y 1-metil-5-alquiltio, composiciones herbicidas que loscontienen, su utilizacion y procedimiento para combatir plantas indeseadas
ES2102549T3 (es) Procedimiento para la preparacion de hidratos de carbono utilizados como agentes tensioactivos y sus precursores.
AR029379A1 (es) Feniluracilos substituidos, procedimiento para estos compuestos para la lucha contra las plantas indeseables